April 26, 2017
Article
After eight years with no new treatments for ovarian cancer, PARP inhibitors and anti-angiogenics are benefiting patients.
Optune Plus Temodar and Keytruda May Result in Brain Tumor Control
ICI Response May Predict Relapse-Free Survival in Liver Cancer
Taking Time to ‘Smell the Roses’
Addressing Pros and Cons of CAR-T Cell Therapy in Melanoma